Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact

Cell biology

  • 555 Articles
  • 0 Posts
  • ← Previous
  • 1
  • 2
  • 3
  • …
  • 55
  • 56
  • Next →
Dsg2 truncation causes a severe intestinal epithelial barrier breakdown and alters microbiome and immune response
Daniela Kugelmann, Alexander García-Ponce, Nadja Thielemann, Mariya Y. Radeva, Maresa Anders, Da Eun Kang, Christian Siadjeu, Natalie Burkard, Anja K.E. Horn, Jessica Neubauer, Matthias Hiermaier, Desalegn T. Egu, Christoph Schmitz, Oliver Kurzai, Katri S. Vuopala, Outi Kuismin, Nicolas Schlegel, Jens Waschke
Daniela Kugelmann, Alexander García-Ponce, Nadja Thielemann, Mariya Y. Radeva, Maresa Anders, Da Eun Kang, Christian Siadjeu, Natalie Burkard, Anja K.E. Horn, Jessica Neubauer, Matthias Hiermaier, Desalegn T. Egu, Christoph Schmitz, Oliver Kurzai, Katri S. Vuopala, Outi Kuismin, Nicolas Schlegel, Jens Waschke
View: Text | PDF

Dsg2 truncation causes a severe intestinal epithelial barrier breakdown and alters microbiome and immune response

  • Text
  • PDF
Abstract

Inflammatory bowel diseases (IBD) including Crohn’s disease (CD) are characterized by impaired intestinal epithelial barrier (IEB) function. Alterations in the desmosomal cadherin desmoglein 2 (Dsg2) have been linked to loss of IEB and intestinal inflammation in IBD. We investigated the pathogenic impact of a cytoplasmatic-truncating mutation in the desmosomal cadherin desmoglein 2 gene (DSG2) in an IBD patient. Genetic analysis of a CD patient revealed a likely pathogenic DSG2 mutation leading to a truncated protein lacking part of the intracellular domain. Generation of an enterocyte-specific mouse model to recapitulate the human mutation resulted in a lethal intestinal barrier defect which was evident in homozygous but not in heterozygous mice. In vitro, barrier defects correlated with changes in Dsg2 mobility and upregulation of pore-forming tight junction protein claudin-2. Organoids derived from heterozygous Dsg2 truncated mice exhibited increased epithelial susceptibility to proinflammatory cytokines. Bulk RNAseq followed by gene ontology analysis in homozygous mice revealed a skewed IL17/IL23 response overlapping with transcriptional changes in patients with CD. Furthermore, 16S rRNA sequencing revealed alterations in microbiome composition in animals that carried the Dsg2 truncation. In summary, a patient-derived mutation in the DSG2 gene causing cytoplasmic truncation in homozygous state induced a lethal intestinal barrier breakdown in mice paralleled by altered gut microbiota and intestinal immune response.

Authors

Daniela Kugelmann, Alexander García-Ponce, Nadja Thielemann, Mariya Y. Radeva, Maresa Anders, Da Eun Kang, Christian Siadjeu, Natalie Burkard, Anja K.E. Horn, Jessica Neubauer, Matthias Hiermaier, Desalegn T. Egu, Christoph Schmitz, Oliver Kurzai, Katri S. Vuopala, Outi Kuismin, Nicolas Schlegel, Jens Waschke

×

Esco2 restrains pathological endothelial-mesenchymal transition through hidden isoform regulation in a Roberts syndrome model
Roy Jung, Sherin Saheera, Chinmay M. Trivedi
Roy Jung, Sherin Saheera, Chinmay M. Trivedi
View: Text | PDF

Esco2 restrains pathological endothelial-mesenchymal transition through hidden isoform regulation in a Roberts syndrome model

  • Text
  • PDF
Abstract

Roberts syndrome is caused by biallelic ESCO2 pathogenic variants, but the mechanisms linking ESCO2 loss to embryonic endothelial failure remain poorly defined. Endothelial cells must maintain identity and resist endothelial-mesenchymal transition (EndMT), yet conventional transcriptomics measures gene abundance rather than isoform composition. Here, using endothelial-specific Esco2 deletion in a mouse model relevant to Roberts syndrome, we show that Esco2 loss causes yolk sac vascular remodeling failure, pathological EndMT, diversion from hemogenic endothelial fate, hemogenic endothelial depletion, impaired hematopoietic output, and embryonic lethality. Short-read single-cell RNA-seq revealed broad endothelial reprogramming, whereas single-cell long-read isoform sequencing uncovered a hidden layer of isoform dysregulation that conventional gene-level analysis failed to resolve. Esco2-deficient endothelium exhibited transcriptome-wide isoform switching, disruption of a multi-tier splicing-factor network, and predicted broad loss or rewiring of protein-coding output. Chromatin occupancy profiling localized Esco2 to exonic regions near alternatively spliced loci, supporting a cotranscriptional route to spliceopathy. Whole-genome sequencing showed that local DNA variation was insufficient to explain these changes, supporting a predominantly posttranscriptional mechanism. These findings identify isoform control as a disease-relevant layer of endothelial identity maintenance in Roberts syndrome.

Authors

Roy Jung, Sherin Saheera, Chinmay M. Trivedi

×

RAD52 is a therapeutic vulnerability for acquired PARP inhibitor resistance in ovarian cancer
Yukihide Ota, Maia L. Elizagaray, Vijayalaxmi Gupta, Bisiayo E. Fashemi, Moreniola Akande, Preedia Babu, Prasanth Kumar Thuthika, Elena Lomonosova, Joshua Brill, Lulu Sun, Brooke Sanders, Lindsay M. Kuroki, Carolyn K. McCourt, Andrea R. Hagemann, Ian S. Hagemann, Premal H. Thaker, David G. Mutch, Matthew A. Powell, Krzysztof Hyrc, Priyanka Verma, John Krais, Benjamin G. Bitler, Mary M. Mullen, Dineo Khabele
Yukihide Ota, Maia L. Elizagaray, Vijayalaxmi Gupta, Bisiayo E. Fashemi, Moreniola Akande, Preedia Babu, Prasanth Kumar Thuthika, Elena Lomonosova, Joshua Brill, Lulu Sun, Brooke Sanders, Lindsay M. Kuroki, Carolyn K. McCourt, Andrea R. Hagemann, Ian S. Hagemann, Premal H. Thaker, David G. Mutch, Matthew A. Powell, Krzysztof Hyrc, Priyanka Verma, John Krais, Benjamin G. Bitler, Mary M. Mullen, Dineo Khabele
View: Text | PDF

RAD52 is a therapeutic vulnerability for acquired PARP inhibitor resistance in ovarian cancer

  • Text
  • PDF
Abstract

Acquired resistance to poly(ADP-ribose) polymerase inhibitors (PARPi) limits their therapeutic benefits in patients with high-grade serous ovarian cancer (HGSC). Identifying therapeutic vulnerabilities that function across distinct forms of acquired PARPi resistance is an urgent need. In BRCA2-deficient PARPi-naive cells, targeting RAD52 can be synthetic lethal with a PARPi, making RAD52 an attractive therapeutic target. However, this approach has not been tested in HGSC models of acquired PARPi resistance. Here, we assessed the effects of RAD52 loss in 2 distinct Brca2-deficient mouse models of HGSC with acquired PARPi resistance. RAD52 loss suppressed homologous recombination and single-strand annealing DNA repair activity in both models. Genetic depletion and pharmacologic inhibition of RAD52 restored PARPi sensitivity both in vitro and in vivo. Furthermore, RAD52 expression was elevated in a newly derived human model of BRCA2-deficient HGSC with acquired PARPi resistance. In this cell line, RAD52 inhibition synergized with a PARPi. Finally, elevated RAD52 expression was associated with poor survival in patients with HGSC. Collectively, these findings establish RAD52 as a clinically relevant therapeutic vulnerability in multiple models of HGSC with acquired PARPi resistance.

Authors

Yukihide Ota, Maia L. Elizagaray, Vijayalaxmi Gupta, Bisiayo E. Fashemi, Moreniola Akande, Preedia Babu, Prasanth Kumar Thuthika, Elena Lomonosova, Joshua Brill, Lulu Sun, Brooke Sanders, Lindsay M. Kuroki, Carolyn K. McCourt, Andrea R. Hagemann, Ian S. Hagemann, Premal H. Thaker, David G. Mutch, Matthew A. Powell, Krzysztof Hyrc, Priyanka Verma, John Krais, Benjamin G. Bitler, Mary M. Mullen, Dineo Khabele

×

αTAT1 links microtubules to stiffness sensing, fibroblast activation, and fibrosis
Alba Santos, Tamanna Islam, Maria-Anna Chrysovergi, Paula E. Grasberger, Vera Auernheimer, Taslim A. Al-Hilal, Santiago Lamas, David Lagares
Alba Santos, Tamanna Islam, Maria-Anna Chrysovergi, Paula E. Grasberger, Vera Auernheimer, Taslim A. Al-Hilal, Santiago Lamas, David Lagares
View: Text | PDF

αTAT1 links microtubules to stiffness sensing, fibroblast activation, and fibrosis

  • Text
  • PDF
Abstract

Matrix stiffening sustains fibrosis by recruiting fibroblasts to stiff fibrotic areas through durotaxis. Once recruited, fibroblasts become mechanically activated and promote scar formation. Although actin-based mechanotransduction and focal adhesion signaling are well established, how microtubules contribute to stiffness sensing and fibroblast activation in fibrosis remains incompletely understood. Here, we identify αTAT1-mediated microtubule acetylation as a key regulator of fibroblast mechanosensing, durotaxis, and profibrotic activation. Through α-tubulin K40 acetylation, αTAT1 promotes microtubule flexibility, directional alignment, and persistent polarity along stiffness gradients, thereby enabling stiffness-directed migration and fibroblast activation. Mechanistically, αTAT1-dependent microtubule acetylation regulates focal adhesion dynamics and downstream mechanotransduction. αTAT1 loss abolishes K40 acetylation, impairs FAK-mediated YAP/TAZ signaling, and prevents stiffness- and TGF-β–induced myofibroblast differentiation. Accordingly, global or fibroblast-specific Atat1 depletion reduces fibroblast durotaxis and the accumulation of profibrotic fibroblasts, protecting mice from lung, dermal, and kidney fibrosis without affecting inflammation or vascular integrity. Our findings establish αTAT1-dependent microtubule acetylation as a conserved mechanosensing pathway that links fibroblast durotaxis and activation to fibrosis across organs in vivo, and identify αTAT1 catalytic activity as a potential mechano-therapeutic target in fibrotic disease.

Authors

Alba Santos, Tamanna Islam, Maria-Anna Chrysovergi, Paula E. Grasberger, Vera Auernheimer, Taslim A. Al-Hilal, Santiago Lamas, David Lagares

×

Genomic, single-cell, and functional profiling of the CD48-CD244 axis and NK cell dysfunction in multiple myeloma
Bonell Patiño-Escobar, Torsten Steinbrunn, Lucy Perez-Lugo, Sham Rampersaud, Daniel D. Waller, Daniela Ordoñez, Huimin Geng, Fernando Salangsang, Paul Phojanakong, Juan Antonio Camara Serrano, Yan Zeng, Veronica Steri, Oscar A. Aguilar, Constantine S. Mitsiades, Arun P. Wiita
Bonell Patiño-Escobar, Torsten Steinbrunn, Lucy Perez-Lugo, Sham Rampersaud, Daniel D. Waller, Daniela Ordoñez, Huimin Geng, Fernando Salangsang, Paul Phojanakong, Juan Antonio Camara Serrano, Yan Zeng, Veronica Steri, Oscar A. Aguilar, Constantine S. Mitsiades, Arun P. Wiita
View: Text | PDF

Genomic, single-cell, and functional profiling of the CD48-CD244 axis and NK cell dysfunction in multiple myeloma

  • Text
  • PDF
Abstract

Multiple myeloma (MM) orchestrates immune evasion by subverting natural killer (NK) cell function. CD48, one of the most abundant NK ligands on MM cells, paradoxically enhances NK cell activation yet is associated with high-risk cytogenetics and poor patient survival. We integrated multiomics (bulk and single-cell RNA-seq, assay for transposase-accessible chromatin using sequencing [ATAC-seq], chromatin immunoprecipitation sequencing [ChIP-seq]), genome-wide CRISPR knockout/activation screens, and machine learning to dissect CD48 regulation and function. In human MM and Vκ*MYC mouse scRNA-seq datasets, NK cells exhibit stepwise increases in inflammatory and exhaustion signatures and loss of cytotoxic potential as disease progresses. In vitro coculture assays show that CD48 overexpression on MM enhances NK cell cytokine secretion, whereas chronic exposure leads to ex vivo NK dysfunction. In vivo, CD48-overexpressing Vκ*MYC tumors progress more slowly and extend host survival, while NK cell depletion accelerates disease. These findings support a context-dependent role for CD48, potentiating acute NK responses while coexisting with chronic NK exhaustion, and suggest strategies to modulate CD48 for therapeutic benefit.

Authors

Bonell Patiño-Escobar, Torsten Steinbrunn, Lucy Perez-Lugo, Sham Rampersaud, Daniel D. Waller, Daniela Ordoñez, Huimin Geng, Fernando Salangsang, Paul Phojanakong, Juan Antonio Camara Serrano, Yan Zeng, Veronica Steri, Oscar A. Aguilar, Constantine S. Mitsiades, Arun P. Wiita

×

CASM regulates lysosomal expansion and cell fate during senescence
Yu-Wei Cheng, Michael Z. Gao, Jay Xiaojun Tan, Jie Liu, Toren Finkel
Yu-Wei Cheng, Michael Z. Gao, Jay Xiaojun Tan, Jie Liu, Toren Finkel
View: Text | PDF

CASM regulates lysosomal expansion and cell fate during senescence

  • Text
  • PDF
Abstract

Cellular senescence, a hallmark of aging, is accompanied by a striking expansion of the cell’s lysosomal compartment, yet the pathway leading to increased lysosomal content remains unresolved. Here, we demonstrate that the master lysosomal transcriptional regulator TFEB is activated during senescence through a pathway that involves conjugation of ATG8 onto single membranes (CASM). Using various senescence inducers, we show that senescence induction triggers robust TFEB nuclear translocation and upregulation of TFEB target genes. In contrast, inhibition of the core CASM machinery by CRISPR-mediated deletion of either ATG16L1, ATG12, or ATG5 markedly reduced senescence-induced TFEB nuclear translocation. In ATG16L1-KO cells, reconstitution with WT ATG16L1 but not the CASM-defective ATG16L1F467A mutant restored both ATG8 lipidation on the lysosomal surface and TFEB activation. Moreover, expression of the Salmonella effector protein SopF, a previously described specific CASM inhibitor, similarly blocked senescence-induced TFEB translocation. Functionally, upon stress, CASM-deficient cells exhibited a pronounced shift away from senescence and toward a cell death fate, a phenotype reversed by expressing a constitutively active form of TFEB. Together, these findings identify CASM-dependent TFEB activation as an essential mechanism enabling senescence-associated lysosomal expansion and suggest that lysosomal capacity modulates cell fate decisions in the aftermath of acute stress.

Authors

Yu-Wei Cheng, Michael Z. Gao, Jay Xiaojun Tan, Jie Liu, Toren Finkel

×

Alveolar Type II Cell-derived MMP1high basal cells promote destructive microcysts in idiopathic pulmonary fibrosis
Marylene Toigo, Kiana Garakani, Alexis N. Brumwell, Ying Wei, Tsung Che Ho, Paul J. Wolters, Michael A. Matthay, Stefano A. Iantorno, Vincent C. Auyeung, Harold A. Chapman, Claude Jourdan Le Saux
Marylene Toigo, Kiana Garakani, Alexis N. Brumwell, Ying Wei, Tsung Che Ho, Paul J. Wolters, Michael A. Matthay, Stefano A. Iantorno, Vincent C. Auyeung, Harold A. Chapman, Claude Jourdan Le Saux
View: Text | PDF

Alveolar Type II Cell-derived MMP1high basal cells promote destructive microcysts in idiopathic pulmonary fibrosis

  • Text
  • PDF
Abstract

Alveolar microcysts, a hallmark of Idiopathic Pulmonary Fibrosis (IPF), are basal cell (BC)-lined structures that develop near terminal airways and correlate with poor clinical outcomes. Using primary-cell organoids and spatial transcriptomics, we identified striking epithelial similarities between respiratory bronchioles (RBs) and IPF alveolar microcysts, both containing AT0 (ABCA3+/SCGB3A2+), SCGB3A2+, and basaloid/BC populations, although basaloid/BCs were markedly expanded in IPF microcysts. A CEACAM6+ subset of normal RB epithelial cells, termed respiratory airway secretory cells (RASCs), consisted predominantly of SCGB3A2+ cells with only rare BCs (1–5%) that by RNA trajectory analysis suggested BCs arise from SCGB3A2+ progenitors. Accordingly, in organoid cultures nearly all RASC-derived colonies converted to BCs within 9 days, resembling colonies generated by purified BCs. BCs derived from either RASCs or normal alveolar type II (AT2) cells strongly expressed the collagenase matrix metalloproteinase-1 (MMP1), recapitulating the phenotype of BCs lining IPF microcysts. MMP1high BCs degraded type I collagen ex vivo and generated microcyst-like structures in vivo following xenotransplantation, both abolished by MMP activity inhibition or specific MMP1 deletion by sh-RNAi. Finally, a Frizzled-5 WNT agonist antibody reversed the MMP1high phenotype, identifying AT2- and RB-derived basal cell transdifferentiation as a previously unrecognized driver of alveolar destruction and microcyst formation in IPF and a potential therapeutic target.

Authors

Marylene Toigo, Kiana Garakani, Alexis N. Brumwell, Ying Wei, Tsung Che Ho, Paul J. Wolters, Michael A. Matthay, Stefano A. Iantorno, Vincent C. Auyeung, Harold A. Chapman, Claude Jourdan Le Saux

×

ROCK2 inhibitor belumosudil overcomes resistance to KRAS inhibition in pancreatic cancer models
Alejandra M. Marinelarena, Thao D. Pham, Jeffrey H. Becker, Apurba Majumder, Hidayatullah G. Munshi
Alejandra M. Marinelarena, Thao D. Pham, Jeffrey H. Becker, Apurba Majumder, Hidayatullah G. Munshi
View: Text | PDF

ROCK2 inhibitor belumosudil overcomes resistance to KRAS inhibition in pancreatic cancer models

  • Text
  • PDF
Abstract

Authors

Alejandra M. Marinelarena, Thao D. Pham, Jeffrey H. Becker, Apurba Majumder, Hidayatullah G. Munshi

×

Characterizing NaV1.7 antisense analgesia through antagonist binding, mRNA expression, and neuraxial distribution
Kaue Malange, Julia Borges Paes Lemes, Briana Noble, Yuvicza Anchondo, Carlos E. Morado-Urbina, Saee Jadhav, Saurabh Yadav, Jingrui Ma, Vineet Augustine, Sara A. Dochnal, Chiraag Kambalimath, Marie Duong, Pedro Alvarez, Bethany Fitzsimmons, Curt Mazur, Holly B. Kordasiewicz, Kim Dore, Hien T. Zhao, Tony Yaksh
Kaue Malange, Julia Borges Paes Lemes, Briana Noble, Yuvicza Anchondo, Carlos E. Morado-Urbina, Saee Jadhav, Saurabh Yadav, Jingrui Ma, Vineet Augustine, Sara A. Dochnal, Chiraag Kambalimath, Marie Duong, Pedro Alvarez, Bethany Fitzsimmons, Curt Mazur, Holly B. Kordasiewicz, Kim Dore, Hien T. Zhao, Tony Yaksh
View: Text | PDF

Characterizing NaV1.7 antisense analgesia through antagonist binding, mRNA expression, and neuraxial distribution

  • Text
  • PDF
Abstract

Genome-targeting strategies to address NaV1.7-mediated signaling in nociceptive afferents are of great clinical interest given its high selectivity and persistent analgesic outcomes. In the present work, we analyze concentration-dependent effects of suppressing primary afferent NaV1.7 using the intrathecal delivery of an antisense oligonucleotide (ASO) on pain behaviors and demonstrate that NaV1.7 ASOs are likely to modulate pain traffic by blocking afferent signaling at the dorsal root ganglion (DRG) level. Intrathecal NaV1.7 ASOs induced a concentration-dependent gradient of knockdown in DRGs (lumbar to cervical) of Scn9a mRNA and ATTO488-ProTx-II binding in small DRG neurons, and a suppression of pain behaviors initiated by mechanical compression, inflammation, and the NaV1.7 agonist OD-1. The rostro-caudal reduction in mRNA correlated with ASO distribution, with implications for dose-related analgesic profiles. Marked reduction in DRG NaV1.7 binding was seen after intrathecal delivery of an ASO optimal dose, with high selectivity for small DRG neurons. Changes in sciatic nerve NaV1.7 binding were not detected, indicating a pain traffic modulation likely happening due to a block of afferent signaling at the DRG level.

Authors

Kaue Malange, Julia Borges Paes Lemes, Briana Noble, Yuvicza Anchondo, Carlos E. Morado-Urbina, Saee Jadhav, Saurabh Yadav, Jingrui Ma, Vineet Augustine, Sara A. Dochnal, Chiraag Kambalimath, Marie Duong, Pedro Alvarez, Bethany Fitzsimmons, Curt Mazur, Holly B. Kordasiewicz, Kim Dore, Hien T. Zhao, Tony Yaksh

×

Tumor stiffness creates a ferroptotic Achilles’ heel through YAP–SKP2 signaling
Emma Villares, Nico Taber, Shao-Chin Wu, Connor Amelung, Jianli Wu, Chao-Chieh Lin, Jen-Tsan Chi, Sharon Gerecht
Emma Villares, Nico Taber, Shao-Chin Wu, Connor Amelung, Jianli Wu, Chao-Chieh Lin, Jen-Tsan Chi, Sharon Gerecht
View: Text | PDF

Tumor stiffness creates a ferroptotic Achilles’ heel through YAP–SKP2 signaling

  • Text
  • PDF
Abstract

Matrix stiffness is a hallmark of aggressive solid tumors and strongly associated with therapeutic resistance and poor prognosis. This mechanical barrier represents a major unmet challenge in oncology, as current strategies rarely address how matrix mechanics themselves drive treatment resistance. Here, we identified ferroptosis, an iron-dependent form of cell death, as a potential long-sought vulnerability that can be exploited to eliminate mechanically resistant tumors. Using genetic and chemical approaches, we investigated how matrix stiffness sensitizes cancer cells to ferroptosis and whether this vulnerability can be therapeutically targeted. We found that cancer cells cultured on stiff matrices were more sensitive to ferroptosis than those on soft matrices, as evidenced by reduced cell viability and elevated lipid peroxidation. Furthermore, we found that matrix stiffness induced YAP activation, which upregulated its target gene SKP2, a key mediator required for the heightened ferroptosis sensitivity observed under stiff conditions. Finally, using an injectable hydrogel system, we demonstrated that stiffened tumors were resistant to chemotherapy but remained highly susceptible to ferroptosis induction, resulting in markedly reduced tumor volume and weight. Our findings established ferroptosis as a stiffness-dependent vulnerability mediated by a YAP-SKP2 signaling axis, revealing a mechanotransductive pathway that may be leveraged to target treatment-refractory tumors.

Authors

Emma Villares, Nico Taber, Shao-Chin Wu, Connor Amelung, Jianli Wu, Chao-Chieh Lin, Jen-Tsan Chi, Sharon Gerecht

×
  • ← Previous
  • 1
  • 2
  • 3
  • …
  • 55
  • 56
  • Next →

No posts were found with this tag.

Advertisement

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts